Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study
暂无分享,去创建一个
[1] H. Yanai,et al. Chronic Kidney Disease Stage G4 in a Diabetic Patient Improved by Multi-Disciplinary Treatments Based Upon Literature Search for Therapeutic Evidence , 2022, Cardiology research.
[2] Akihiko Kato,et al. Lifestyle-Related Risk Factors for the Incidence and Progression of Chronic Kidney Disease in the Healthy Young and Middle-Aged Population , 2022, Nutrients.
[3] A. Panayiotou,et al. The Effect of Fibrates on Kidney Function and Chronic Kidney Disease Progression: A Systematic Review and Meta-Analysis of Randomised Studies , 2022, Journal of clinical medicine.
[4] H. Katsuyama,et al. Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease , 2021, International journal of molecular sciences.
[5] H. Katsuyama,et al. Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors , 2021, International journal of molecular sciences.
[6] H. Yanai,et al. Secondary dyslipidemia: its treatments and association with atherosclerosis. , 2021, Global health & medicine.
[7] Shu Li,et al. Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis , 2021, Renal failure.
[8] F. Lugani,et al. Serum indoxyl sulfate concentrations associate with progression of chronic kidney disease in children , 2020, PloS one.
[9] G. Filippatos,et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. , 2020, The New England journal of medicine.
[10] J. McMurray,et al. Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.
[11] Yung-Ming Chen,et al. Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta‐Analysis , 2020, Clinical pharmacology and therapeutics.
[12] T. Hosoya,et al. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study , 2019, Clinical and Experimental Nephrology.
[13] Koji Matsumoto,et al. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor , 2019, The Journal of Pharmacology and Experimental Therapeutics.
[14] L. Ruilope,et al. Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis , 2019, Blood pressure.
[15] F. Jaisser,et al. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. , 2019, Kidney international.
[16] B. Zinman,et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.
[17] B. Zinman,et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.
[18] C. Bailey. Uric acid and the cardio‐renal effects of SGLT2 inhibitors , 2019, Diabetes, obesity & metabolism.
[19] N. Shinomiya,et al. Identification of ABCG2 as an Exporter of Uremic Toxin Indoxyl Sulfate in Mice and as a Crucial Factor Influencing CKD Progression , 2018, Scientific Reports.
[20] R. Klopfleisch,et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic Activity , 2018, Hypertension.
[21] R. Guthrie. Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.
[22] C. Ferri. The problem of cardio-renal diseases in patients with gout , 2017, Current medical research and opinion.
[23] M. E. Ramirez,et al. Treatment of asymptomatic hyperuricemia in chronic kidney disease: A new target in an old enemy – A review , 2017, Journal of advanced research.
[24] I. D. de Boer. Liraglutide and Renal Outcomes in Type 2 Diabetes. , 2017, The New England journal of medicine.
[25] Hirotaka Matsuo,et al. Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations , 2016, Front. Pharmacol..
[26] Lawrence A Leiter,et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.
[27] John M Lachin,et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.
[28] D. Waters. LDL-cholesterol lowering and renal outcomes , 2015, Current opinion in lipidology.
[29] C. Clase,et al. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis , 2015, BMC Nephrology.
[30] J. Wang,et al. Hyperuricemia and Risk of Incident Hypertension: A Systematic Review and Meta-Analysis of Observational Studies , 2014, PloS one.
[31] Fang Liu,et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies , 2014, BMC Nephrology.
[32] Ping Zhu,et al. Serum Uric Acid Is Associated with Incident Chronic Kidney Disease in Middle-Aged Populations: A Meta-Analysis of 15 Cohort Studies , 2014, PloS one.
[33] K. Dwan,et al. Allopurinol for the treatment of chronic kidney disease: a systematic review. , 2014, Health technology assessment.
[34] P. Richette,et al. Definition of hyperuricemia and gouty conditions , 2014, Current opinion in rheumatology.
[35] Y. Shinohara,et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia , 2012, Nature Communications.
[36] H. Saito,et al. The Increased Protein Level of URAT1 was Observed in Obesity/Metabolic Syndrome Model Mice , 2011, Nucleosides, nucleotides & nucleic acids.
[37] Hyon K. Choi,et al. Hyperuricemia and incident hypertension: A systematic review and meta‐analysis , 2011, Arthritis care & research.
[38] Nicola Dalbeth,et al. The genetic basis of hyperuricaemia and gout. , 2011, Joint, bone, spine : revue du rhumatisme.
[39] N. Hamajima,et al. Common Defects of ABCG2, a High-Capacity Urate Exporter, Cause Gout: A Function-Based Genetic Analysis in a Japanese Population , 2009, Science Translational Medicine.
[40] E. Boerwinkle,et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout , 2009, Proceedings of the National Academy of Sciences.
[41] Dongmei Meng,et al. Insulin resistance acts as an independent risk factor exacerbating high-purine diet induced renal injury and knee joint gouty lesions , 2009, Inflammation Research.
[42] T. Merriman,et al. Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout. , 2008, Rheumatology.
[43] G. Punzo,et al. Uric acid: bystander or culprit in hypertension and progressive renal disease? , 2008, Journal of hypertension.
[44] P. Elliott,et al. SLC2A9 Is a High-Capacity Urate Transporter in Humans , 2008, PLoS medicine.
[45] William A. Richardson,et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout , 2008, Nature Genetics.
[46] S. Bandinelli,et al. The GLUT9 Gene Is Associated with Serum Uric Acid Levels in Sardinia and Chianti Cohorts , 2007, PLoS genetics.
[47] M. Calabozo,et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. , 2002, Arthritis and rheumatism.
[48] Hirotaka Matsuo,et al. Molecular identification of a renal urate–anion exchanger that regulates blood urate levels , 2002, Nature.
[49] G. Klöppel,et al. Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. , 2008, Liver.
[50] H. Simmonds,et al. Polynesian women are also at risk for hyperuricaemia and gout because of a genetic defect in renal urate handling. , 1994, British journal of rheumatology.
[51] Y. Horsmans,et al. Subfulminant hepatitis requiring liver transplantation after benzarone administration. , 1994, Journal of hepatology.
[52] K. Bremner,et al. Hyperuricaemia, gout and kidney function in New Zealand Maori men. , 1984, British journal of rheumatology.